{"id":958,"date":"2019-12-04T16:22:32","date_gmt":"2019-12-04T15:22:32","guid":{"rendered":"https:\/\/dose-innova.ccoo.cat\/?p=958"},"modified":"2019-12-04T16:22:32","modified_gmt":"2019-12-04T15:22:32","slug":"por-cumplimiento-de-un-deber-inexcusable-2","status":"publish","type":"post","link":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/por-cumplimiento-de-un-deber-inexcusable-2\/","title":{"rendered":"Per compliment d&#8217;un deure inexcusable"},"content":{"rendered":"<p>Pel temps indispensable per al compliment d&#8217;un deure inexcusable de car\u00e0cter p\u00fablic i personal, compr\u00e8s l&#8217;exercici del sufragi actiu. Quan consti en una norma legal o convencional un per\u00edode determinat, com \u00e9s el cas de l&#8217;exercici de sufragi actiu, s&#8217;estar\u00e0 al que aquesta disposi quant a durada de l&#8217;abs\u00e8ncia i compensaci\u00f3 econ\u00f2mica. En la resta de sup\u00f2sits, els treballadors que el dia anterior al compliment del deure inexcusable de car\u00e0cter p\u00fablic i personal tinguin assignat torn de nit podran gaudir del perm\u00eds retribu\u00eft durant aquest \u00faltim, sempre que la citaci\u00f3 al corresponent deure sigui anterior a les 14.00 hores.    \t    \t<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pel temps indispensable per al compliment d&#8217;un deure inexcusable de car\u00e0cter p\u00fablic i personal, compr\u00e8s l&#8217;exercici del sufragi actiu. Quan consti en una norma legal o convencional un per\u00edode determinat, &#8230; <a title=\"Per compliment d&#8217;un deure inexcusable\" class=\"read-more\" href=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/por-cumplimiento-de-un-deber-inexcusable-2\/\" aria-label=\"Leer m\u00e1s sobre Per compliment d&#8217;un deure inexcusable\">Leer m\u00e1s<\/a><\/p>\n","protected":false},"author":59,"featured_media":346,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[],"class_list":["post-958","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-permisosllicencies_ca","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"_links":{"self":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/comments?post=958"}],"version-history":[{"count":0,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/958\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media\/346"}],"wp:attachment":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media?parent=958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/categories?post=958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/tags?post=958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}